Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023

-
Image
pediatrics associates of dallas :: Article Creator Pediatric Diagnostic Associates Will Continue Serving Families As A Practice Independent Of CHI Memorial Pediatric Diagnostic Associates, which was previously associated with CHI Memorial Hospital, announced Thursday it will again become an independent practice under newly formed Scenic City Pediatrics PLLC. Effective Feb. 1, the medical group will enter a new contract with BlueCross BlueShield of Tennessee, including Networks P and S, among other insurers, according to a news release. The change follows a June decision on BlueCross BlueShield of Tennessee's behalf to terminate its contract with Memorial relating to its Network S customers. Managing Partner Dr. Tony Friddell said in a phone interview Pediatric Diagnostic Associates has been under the CHI Memorial umbrella as a managed practice within the hospital system for 28 years. In some shape or form, Pediatric Diagnostic Associates...
Post a Comment

CDC Updates Pneumococcal Vaccine Recommendations - Contagionlive.com

-
The United States Centers for Disease Control and Prevention (CDC) has updated pneumococcal vaccine recommendations, based on the Advisory Committee on Immunization Practices (ACIP’s) evaluation of their 2014 recommendation for Pneumococcal Conjugate Vaccine (PCV13) use among adults aged ≥65 years. The update was published in the CDC’s Morbidity and Mortality Weekly Report (MMWR).

The committee found that PCV13 use among children has indirectly helped reduce incidence of PCV13-type disease to historic lows among adults. As a result, they have removed the recommendation for routine PCV13 vaccination among adults aged ≥65 years. ACIP now recommends PCV13 administration in the aged ≥65 years population based on shared clinical decision-making which incorporates risk for exposure to PCV13 serotypes.

The committee continues to recommend PCV13 in series with Pneumococcal Polysaccharide Vaccine (PPSV23) for adults ≥19 years of age who have an immunocompromising condition, cochlear implants, or cerebrospinal fluid leaks.

Results were assessed through the 2016-2019 Evidence to Recommendations Framework. The ACIP Pneumococcal Vaccines Work Group conducted a systematic review of scientific literature published from January 1, 2014, through July 3, 2018, in order to identify studies that evaluated direct and indirect effects of vaccination with PCV13 on in invasive pneumococcal disease, pneumonia, and mortality.

While 364 studies were identified for in-depth review, 344 did not use PCV13 or did not include an outcome or population of interest. The remaining 20 studies were included in the analysis. The goal of the analysis was to assess whether PCV13 should be administered routinely to all immunocompetent adults aged ≥65 years in context of the indirect effects of pediatric PCV use.

During the 2000-14 period, incidence of PCV13-type invasive pneumococcal disease declined 9-fold among adults aged ≥65 years. From 2014-17, the period after the recommendation was made, no further reduction in PCV13-type invasive pneumococcal disease was observed in the ≥65 years adult population, with incidence remaining stable at 5 of 100,000 population.

Authors of the MMWR report did note a single unpublished cohort study that found a 31.5% reduction in PCV13-type pneumonia and a 13.8% reduction in all-cause pneumonia between 2014-15 and 2015-16. However, overall the authors concluded that since the 2014 recommendations were announced, minimal changes in incidence of pneumococcal disease among adults at the population-level were observed.

An economic analysis was also conducted, with 2 models that evaluated the expected public health impact and cost effectiveness of PCV13 use in series with PPSV23 compared to use of PPSV23 alone.

The models estimated that for a cohort of 2.7 million adults aged 65 years, an expected 76-175 cases of PCV13-type invasive pneumococcal disease and 4000-11,000 cases of PCV13-type pneumonia would be averted through continued PCV13 use in series with PPSV23, compared to PPSV23 alone.

Estimated cost effectiveness rations based on total costs to quality adjusted life years (QALY) were $200,000 to $560,000 per QALY. In 2014, at time of recommendation, the estimated cost per QALY for PCV13 use in series with PPSV23 was $65,000.

In making 2014 recommendations for routine PCV13 administration among adults aged ≥65 years, ACIP recognized that in the long-term, continued indirect effects of PCV13 use among children might limit the utility of the recommendation. Models at the time predicted limited long-term public health benefits due to an already relatively low remaining PCV13-type disease burden. Results appear to have confirmed this assessment.

While the report maintained that PCV13 is a safe and effective vaccine that can reduce risk for PCV13-type invasive pneumococcal disease and noninvasive pneumonia among persons aged ≥65 years, ACIP no longer recommends routine administration for all adults aged ≥65 years in favor of risk-based shared clinical decision-making. The decision, based on historically low levels of PCV13-type disease incidence, highlights the gains made by pediatric PCV13 vaccine uptake.

To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


https://ift.tt/34qWUv9

Comments

Post a Comment

Popular posts from this blog

These Are the Top Doctors in the Hudson Valley in 2022

-
Image
advanced primary care of the ozarks :: Article Creator Integrating Rx With Advanced Primary Care Will Unlock Better Health America's healthcare industry has been squeezed tightly over the past few years with post-pandemic fallout, a declining economy and high consumer expectations. Retail pharmacies are no exception, and it's clear that the traditional pharmacy model is in crisis. With rising costs for medications and supplies and changing consumer retail habits, this doesn't bode well for the brick-and-mortar community pharmacy. Simply put: the traditional pharmacy model is unsustainable. We will soon see a rash of closing retail pharmacies and consumers scrambling to fill needed prescriptions affordably. You might be asking yourself why this should matter to you as HR and benefit professionals. I serve as chief human resources officer for a company that works with many large employers concerned about healthcare costs and the de...
Read more

William Buoni, MD - Wexner Medical Center

-
Image
podiatry billing company :: Article Creator The Best Medical Billing Services Of 2024 1. Get a full picture of the company's features. Claim scrubbing and follow-up are par for the course. You'll also commonly find that RCM companies include reporting, consultation, and EMR and PMS access with your services. Check for these features as you speak with company representatives. You should also determine whether the features that accompany your medical billing leave the company or your own team responsible for entering and coding charges. It's worth asking if your billing service candidates are following the most recent ICD-10 coding system updates. You should also get a sense of the billing company's experience with other practices in your specialty. Lastly, ask about the depth and extent of reporting and analytics solutions. "You'll want to ensure that your medical billing service has implemented & maintains timely bill...
Read more

Who are the top doctors in Columbus? Search by specialty with Columbus Monthly's 2021 list

-
Image
women's preventive services :: Article Creator Women - Search News Team USA wins women's 4x400 for eighth consecutive Olympic gold medal The U.S. Women's have dominated the 4x400 relay, winning eight golds in a row in the event. When Team USA won it in Tokyo it gave the legendary Allyson Felix her 11th Olympic medal, making her the most decorated track and field athlete of all time.
Read more